CLAIMS:

1. A pharmaceutical composition comprising:
(a) an isolated uricase comprising an amino acid sequence of SEQ ID NO. 7; and
(b) a pharmaceutically acceptable carrier;
wherein the uricase is conjugated with a polymer.

2. A pharmaceutical composition comprising:
(a) a uricase comprising an amino acid sequence of SEQ ID NO. 8; and
(c) a pharmaceutically acceptable carrier
(b) wherein the uricase is conjugated with a polymer.

3. The pharmaceutical composition of claim 1, wherein the uricase further comprises amino terminal amino acid, wherein the amino terminal amino acid is alanine, glycine, proline, serine, or threonine.

4. The pharmaceutical composition of any one of claims 1 and 2, wherein the polymer is selected from the group consisting of poly(ethylene glycol), dextran, polypropylene glycol, hydroxypropylmethyl cellulose, carboxymethylcellulose, polyvinyl pyrrolidone and polyvinyl alcohol.

5. The pharmaceutical composition of claim 4 comprising 2-12 polyethylene glycol moieties on each uricase subunit.

6. The pharmaceutical composition of claim 5 comprising 3-10 polyethylene glycol moieties on each uricase subunit.

7. The pharmaceutical composition of claim 4, wherein each polyethylene glycol moiety has a molecular weight of about 1 kD and 100 kD.

8. The pharmaceutical composition of claim 7, wherein each polyethylene glycol moiety has a molecular weight of about 1 kD and 50 kD.

9. The pharmaceutical composition of claim 8, wherein each polyethylene glycol moiety has a molecular weight of about 5 kD and 20 kD.

10. The pharmaceutical composition of claim 9, wherein each polyethylene glycol moiety has a molecular weight of about 10 kD.

11. A method for preparing a pharmaceutical composition for reducing uric acid levels in a biological fluid of a subject in need thereof, comprising: (a) preparing a conjugate of the uricase of SEQ ID NO:7 with a polymer; and (b) adding the uricase conjugate to a pharmaceutically acceptable carrier.

12. A method for preparing a pharmaceutical composition for reducing uric acid levels in a biological fluid of a subject in need thereof, comprising: (a) preparing a conjugate of the uricase of SEQ ID NO:8 with a polymer; and (b) adding the uricase conjugate to a pharmaceutically acceptable carrier.

13. The method of claim 11, wherein the biological fluid is blood.

14. The method of claim 12, wherein the biological fluid is blood.

15. The method of claim 11, wherein the polymer is selected from the group consisting of poly(ethylene glycol), dextran, polypropylene glycol, hydroxypropylmethyl cellulose, carboxymethylcellulose, polyvinyl pyrrolidone and polyvinyl alcohol.

16. The method of claim 12, wherein the polymer is selected from the group consisting of poly(ethylene glycol), dextran, polypropylene glycol, hydroxypropylmethyl cellulose, carboxymethylcellulose, polyvinyl pyrrolidone and polyvinyl alcohol.